Compare GSK plc (GSK) vs Zillow Group Inc Class C (Z) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Zillow Group (Z) trades at $33.83, up 6.18% today, with a bullish technical signal but mixed indicators. The company shows improving fundamentals, with revenue growing to $2.58B in 2025 and a return to profitability (net income of $23M). However, a high P/E ratio of 135.38 indicates premium valuation, and negative net cash flow persists. Recent news highlights multiple securities class action lawsuits alleging fraud related to an anticompetitive agreement, creating significant headline risk.

The outlook is cautious; while analyst consensus is a Buy with a $57.67 price target implying substantial upside, near-term sentiment is pressured by litigation. The key opportunity lies in continued execution on revenue growth and margin expansion, but investors face elevated risks from legal proceedings and the stock's high valuation multiples.